Developer docs
API playgroundTry for free, no card

Search company profiles

Mapol

Full company profile

uuid002bof5

Namestring
Mapol
Legal namestring
Mapol Inc.
Websiteurl
mapol.ca
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Mapol Inc. is a Canadian market access consulting firm founded in 2012 and headquartered in Mississauga, Ontario. The company serves innovative pharmaceutical manufacturers seeking to navigate Canada's private and public payer drug plans, from regulatory approval through formulary listing and reimbursement adoption. Its offerings are organized around three pillars: Payer Strategy (landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support), Data Services (Drug Reimbursement Monitor [DRM] Reports described as an industry-standard benchmark, plus custom Claims Analytics and Time-to-Listing forecasts), and Payer Engagement (submission support, Canada's leading accredited payer webinar series with over 100 sessions, and direct stakeholder meetings). The supporting technology platform aggregates more than 2,000,000 proprietary data points on drug coverage across Canadian plans.

The company monetizes through two primary streams: (1) a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing reports, a weekly Rapid Intelligence Monitor, and the monthly Drug Benefit Communiqué® — relied on by 450+ members across Canada's pharmaceutical industry; and (2) project-based market access consulting engagements billed as professional services. Pricing is not publicly disclosed; subscriptions and consulting are quote-based. The firm operates a direct enterprise sales motion via website contact, phone, and email outreach to pharmaceutical manufacturers, positioning itself as an extension of the client's market access team. It also runs a French-language site variant and complies with PIPEDA, Quebec Law 25, WCAG 2.1 AA, and AODA accessibility standards.

Mapol is a privately held, founder-owned company with a small team (1-10 employees) led by co-founder Johnny Ma (President & COO), a pharmacist with 25+ years of experience including prior tenure as a private payer decision-maker. The leadership bench includes directors overseeing operations, data services, client services, and finance/marketing. The firm operates exclusively in the Canadian market and has supported patient access for hundreds of drugs since inception. No external funding rounds, institutional investors, or M&A activity are disclosed in the available data.

Short descriptiontext

Mapol Inc. is a Canadian market access consulting firm that helps innovative pharmaceutical manufacturers navigate private and public payer drug plans via payer strategy, data analytics (DRM Reports, Claims Analytics, Time-to-Listing forecasts), and stakeholder engagement, supported by a 450+-member MAES subscription and Canada's leading accredited payer webinar series.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical market access, payer strategy consulting, drug reimbursement analytics, market access intelligence, formulary listing support
Industry1 code
PRIMARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
Product category
Pharmaceutical Market Access Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1MAES Subscription (Market Access Essential Services)
TypeSubscription Recurring
Description

Subscription-based membership providing payer profiles, tools, and insights including Rapid Intelligence Monitor (weekly), Drug Benefit Communiqué (monthly), payer profiles, submission guides, stakeholder maps, and time-to-listing reports. Over 450 members subscribe to this service.

mapol.ca
2Market Access Consulting Services
TypeProfessional Services
Description

Custom consulting engagements covering payer strategy (landscape assessments, payer advisory boards, market access support), data services, and payer engagement (submissions, webinar series, stakeholder meetings). Billed as professional services engagements.

mapol.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Drug Reimbursement Monitor (DRM)
Description

Industry standard reports for drug coverage intelligence measuring quality of coverage and lives facing reimbursement barriers across private and public plans.

mapol.ca
+3 more records
Core offering1 text field

Mapol is a market access solutions provider that helps innovative pharmaceutical manufacturers navigate Canada's private and public payer drug plans. It combines three core service areas—Payer Strategy (landscape assessments, payer advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports and Claims Analytics), and Payer Engagement (submissions, accredited webinar series, stakeholder meetings)—alongside the Market Access Essential Services (MAES) subscription membership.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Supported patient access for hundreds of drugs from submission to formulary listing
+2 more records
Product overview1 text field

Mapol is a market access solutions provider offering an integrated platform combining three core service areas: Payer Strategy (landscape assessments, advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports, Claims Analytics), and Payer Engagement (submissions, Payer Webinar Series, stakeholder meetings). These services are delivered alongside a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, the Rapid Intelligence Monitor weekly briefing, and Drug Benefit Communique monthly bulletin. The company focuses exclusively on helping innovative pharmaceutical manufacturers navigate Canada's private and public drug plans since 2012.

Product and service10 records
1Payer Strategy
CategoryConsulting
Description

Strategic consulting services helping innovative pharmaceutical manufacturers anticipate payer responses through landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support from submission through listing and beyond.

2Data Services
CategoryData Analytics
Description

Data analytics offerings centered on Drug Reimbursement Monitor (DRM) Reports providing industry-standard coverage intelligence and claims analytics revealing how plan design shapes real-world utilization patterns across private and public payer plans.

3Payer Engagement
CategoryEngagement Services
Description

Services connecting pharmaceutical manufacturers with private and public payers through submissions to insurers and PLA consortiums, Canada's leading accredited payer webinar series, and direct one-on-one stakeholder meetings with drug plan managers, benefits advisors, and decision-makers.

4Market Access Essential Services (MAES)
CategorySubscription Membership
Description

A comprehensive subscription membership providing payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, rapid intelligence monitoring, and the Drug Benefit Communiqué monthly bulletin, relied on by 450+ members across Canada's pharmaceutical companies.

5Drug Reimbursement Monitor (DRM) Reports
CategoryData Product
Description

The industry-standard benchmark for drug coverage intelligence measuring coverage quality and lives facing reimbursement barriers across private and public plans, with snapshot analysis, uptake tracking, and pre-launch forecasting.

6Claims Analytics
CategoryData Product
Description

Custom analyses revealing how plan design (managed formularies, prior authorization, tiering) shapes real-world claims patterns over time, down to regional and sales-territory level.

7Payer Webinar Series
CategoryEngagement Product
Description

Canada's leading continuing-education webinar series with over 100 C.E.-accredited sessions connecting pharmaceutical manufacturers with the private payer community of insurers, benefits advisors, PBMs, TPAs, and employers.

8Rapid Intelligence Monitor
CategoryIntelligence Product
Description

A weekly summary of changes to private and public payer market access policies, included in the MAES membership.

9Drug Benefit Communiqué
CategoryIntelligence Product
Description

A registered monthly digest with timely analysis of policy changes impacting private and public payer plans, included in the MAES membership.

10Time-to-Listing Reports
CategoryForecast Product
Description

Forecasts of uptake in private payer plans based on historical time-to-listing benchmarks, included in the MAES membership.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
1PDCI Market Access
TypeDirect peer
Description

Canadian market access and reimbursement consulting firm serving pharmaceutical manufacturers with pricing, reimbursement, and health economics services — the closest direct peer to Mapol in Canada.

2IQVIA
TypeBroad incumbent
Description

Global life sciences data and consulting powerhouse offering market access, HEOR, RWE, and commercial services across all major geographies; competes with Mapol for manufacturer market access budgets at the high end.

3ZS Associates
TypeBroad incumbent
Description

Global management consulting and analytics firm with a deep pharmaceutical practice covering market access, launch excellence, and sales/marketing — competes for the same manufacturer clients with broader capabilities.

4Trinity Life Sciences
TypeBroad incumbent
Description

Life sciences commercial consulting firm offering market access, evidence, and brand strategy services — overlaps with Mapol's payer strategy and engagement offerings for innovative pharma manufacturers.

5Evidera (PPD / Thermo Fisher)
TypeBroad incumbent
Description

Health economics, outcomes research, and market access consultancy providing payer evidence and reimbursement strategy — competes for similar manufacturer budgets on the evidence and strategy side.

6Innomar Strategies (Cencora)
TypeRegional player
Description

Canadian pharma services firm (now part of Cencora) offering patient support, market access, and distribution services — directly comparable Canadian-focused competitor with broader patient services reach.

7Syneos Health
TypeBroad incumbent
Description

Global biopharmaceutical services organization with consulting and commercialization capabilities, including market access and payer engagement — competes for innovative manufacturer engagements.

8BresMed
TypeEmerging player
Description

Health economics and market access consultancy serving pharma and medical device clients across multiple geographies — overlapping but more specialized in HEOR than Mapol's payer-focused practice.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mapol

Pharmaceutical Market Access Consultingmapol.ca

Mapol Inc. is a Canadian market access consulting firm that helps innovative pharmaceutical manufacturers navigate private and public payer drug plans via payer strategy, data analytics (DRM Reports, Claims Analytics, Time-to-Listing forecasts), and stakeholder engagement, supported by a 450+-member MAES subscription and Canada's leading accredited payer webinar series.

What Mapol does

Mapol Inc. is a Canadian market access consulting firm founded in 2012 and headquartered in Mississauga, Ontario. The company serves innovative pharmaceutical manufacturers seeking to navigate Canada's private and public payer drug plans, from regulatory approval through formulary listing and reimbursement adoption. Its offerings are organized around three pillars: Payer Strategy (landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support), Data Services (Drug Reimbursement Monitor [DRM] Reports described as an industry-standard benchmark, plus custom Claims Analytics and Time-to-Listing forecasts), and Payer Engagement (submission support, Canada's leading accredited payer webinar series with over 100 sessions, and direct stakeholder meetings). The supporting technology platform aggregates more than 2,000,000 proprietary data points on drug coverage across Canadian plans.

The company monetizes through two primary streams: (1) a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing reports, a weekly Rapid Intelligence Monitor, and the monthly Drug Benefit Communiqué® — relied on by 450+ members across Canada's pharmaceutical industry; and (2) project-based market access consulting engagements billed as professional services. Pricing is not publicly disclosed; subscriptions and consulting are quote-based. The firm operates a direct enterprise sales motion via website contact, phone, and email outreach to pharmaceutical manufacturers, positioning itself as an extension of the client's market access team. It also runs a French-language site variant and complies with PIPEDA, Quebec Law 25, WCAG 2.1 AA, and AODA accessibility standards.

Mapol is a privately held, founder-owned company with a small team (1-10 employees) led by co-founder Johnny Ma (President & COO), a pharmacist with 25+ years of experience including prior tenure as a private payer decision-maker. The leadership bench includes directors overseeing operations, data services, client services, and finance/marketing. The firm operates exclusively in the Canadian market and has supported patient access for hundreds of drugs since inception. No external funding rounds, institutional investors, or M&A activity are disclosed in the available data.

Mapol firmographics

Firmographics
Name
Mapol
Legal name
Mapol Inc.
Website
https://mapol.ca
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Mapol Inc. is a Canadian market access consulting firm that helps innovative pharmaceutical manufacturers navigate private and public payer drug plans via payer strategy, data analytics (DRM Reports, Claims Analytics, Time-to-Listing forecasts), and stakeholder engagement, supported by a 450+-member MAES subscription and Canada's leading accredited payer webinar series.
Ownership category
akta.pro rank

Mapol industry classification

Industry
Product category
Pharmaceutical Market Access Consulting
akta.pro industry
PRIMARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Pharmaceutical market access
  • Payer strategy consulting
  • Drug reimbursement analytics
  • Market access intelligence
  • Formulary listing support

Where Mapol is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Mapol business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. MAES Subscription (Market Access Essential Services): Subscription-based membership providing payer profiles, tools, and insights including Rapid Intelligence Monitor (weekly), Drug Benefit Communiqué (monthly), payer profiles, submission guides, stakeholder maps, and time-to-listing reports. Over 450 members subscribe to this service.
  2. Market Access Consulting Services: Custom consulting engagements covering payer strategy (landscape assessments, payer advisory boards, market access support), data services, and payer engagement (submissions, webinar series, stakeholder meetings). Billed as professional services engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Mapol product offering

Product offering

Core offering

Mapol is a market access solutions provider that helps innovative pharmaceutical manufacturers navigate Canada's private and public payer drug plans. It combines three core service areas—Payer Strategy (landscape assessments, payer advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports and Claims Analytics), and Payer Engagement (submissions, accredited webinar series, stakeholder meetings)—alongside the Market Access Essential Services (MAES) subscription membership.

Product overview

Mapol is a market access solutions provider offering an integrated platform combining three core service areas: Payer Strategy (landscape assessments, advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports, Claims Analytics), and Payer Engagement (submissions, Payer Webinar Series, stakeholder meetings). These services are delivered alongside a subscription membership called Market Access Essential Services (MAES), which provides payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, the Rapid Intelligence Monitor weekly briefing, and Drug Benefit Communique monthly bulletin. The company focuses exclusively on helping innovative pharmaceutical manufacturers navigate Canada's private and public drug plans since 2012.

Differentiator

Problem solved

Functional benefit

Brands

  • Drug Reimbursement Monitor (DRM): Industry standard reports for drug coverage intelligence measuring quality of coverage and lives facing reimbursement barriers across private and public plans.
  • Drug Benefit Communiqué®
  • Rapid Intelligence Monitor
  • Market Access Essential Services (MAES)

Products and services

  • Payer Strategy Strategic consulting services helping innovative pharmaceutical manufacturers anticipate payer responses through landscape assessments, payer advisory boards with former decision-makers, and hands-on market access support from submission through listing and beyond.
  • Data Services Data analytics offerings centered on Drug Reimbursement Monitor (DRM) Reports providing industry-standard coverage intelligence and claims analytics revealing how plan design shapes real-world utilization patterns across private and public payer plans.
  • Payer Engagement Services connecting pharmaceutical manufacturers with private and public payers through submissions to insurers and PLA consortiums, Canada's leading accredited payer webinar series, and direct one-on-one stakeholder meetings with drug plan managers, benefits advisors, and decision-makers.
  • Market Access Essential Services (MAES) A comprehensive subscription membership providing payer profiles, submission guides, stakeholder maps, time-to-listing forecasts, rapid intelligence monitoring, and the Drug Benefit Communiqué monthly bulletin, relied on by 450+ members across Canada's pharmaceutical companies.
  • Drug Reimbursement Monitor (DRM) Reports The industry-standard benchmark for drug coverage intelligence measuring coverage quality and lives facing reimbursement barriers across private and public plans, with snapshot analysis, uptake tracking, and pre-launch forecasting.
  • Claims Analytics Custom analyses revealing how plan design (managed formularies, prior authorization, tiering) shapes real-world claims patterns over time, down to regional and sales-territory level.
  • Payer Webinar Series Canada's leading continuing-education webinar series with over 100 C.E.-accredited sessions connecting pharmaceutical manufacturers with the private payer community of insurers, benefits advisors, PBMs, TPAs, and employers.
  • Rapid Intelligence Monitor A weekly summary of changes to private and public payer market access policies, included in the MAES membership.
  • Drug Benefit Communiqué A registered monthly digest with timely analysis of policy changes impacting private and public payer plans, included in the MAES membership.
  • Time-to-Listing Reports Forecasts of uptake in private payer plans based on historical time-to-listing benchmarks, included in the MAES membership.

Quantifiable outcome

  • Supported patient access for hundreds of drugs from submission to formulary listing
  • +2 more outcomes

Companies that use Mapol

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Mapol technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mapol partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights2 records

Mapol competitors and assessment

Company assessment

Direct peers

  • PDCI Market Access: Canadian market access and reimbursement consulting firm serving pharmaceutical manufacturers with pricing, reimbursement, and health economics services — the closest direct peer to Mapol in Canada.

Broad incumbents

  • IQVIA: Global life sciences data and consulting powerhouse offering market access, HEOR, RWE, and commercial services across all major geographies; competes with Mapol for manufacturer market access budgets at the high end.
  • ZS Associates: Global management consulting and analytics firm with a deep pharmaceutical practice covering market access, launch excellence, and sales/marketing — competes for the same manufacturer clients with broader capabilities.
  • Trinity Life Sciences: Life sciences commercial consulting firm offering market access, evidence, and brand strategy services — overlaps with Mapol's payer strategy and engagement offerings for innovative pharma manufacturers.
  • Evidera (PPD / Thermo Fisher): Health economics, outcomes research, and market access consultancy providing payer evidence and reimbursement strategy — competes for similar manufacturer budgets on the evidence and strategy side.
  • Syneos Health: Global biopharmaceutical services organization with consulting and commercialization capabilities, including market access and payer engagement — competes for innovative manufacturer engagements.

Regional players

  • Innomar Strategies (Cencora): Canadian pharma services firm (now part of Cencora) offering patient support, market access, and distribution services — directly comparable Canadian-focused competitor with broader patient services reach.

Emerging players

  • BresMed: Health economics and market access consultancy serving pharma and medical device clients across multiple geographies — overlapping but more specialized in HEOR than Mapol's payer-focused practice.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Mapol social profiles

Digital presence

Mapol compliance and trust

Trust signal

Compliance2 records

Mapol financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mapol leadership team

Management profile

Number of profiles

Profiles9 records

Mapol funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mapol M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mapol

What does Mapol do?

Mapol is a market access solutions provider that helps innovative pharmaceutical manufacturers navigate Canada's private and public payer drug plans. It combines three core service areas—Payer Strategy (landscape assessments, payer advisory boards, market access support), Data Services (Drug Reimbursement Monitor Reports and Claims Analytics), and Payer Engagement (submissions, accredited webinar series, stakeholder meetings)—alongside the Market Access Essential Services (MAES) subscription membership.

Is Mapol a public or private company?

Mapol is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mapol founded?

Mapol was founded in 2012. It employs 11 to 50 people.

Where is Mapol based?

Mapol is headquartered in Mississauga, Canada, in the North America region.

How does Mapol make money?

Two revenue lines are on record. MAES Subscription (Market Access Essential Services) is the primary driver. The others are market Access Consulting Services.

Who are Mapol's main competitors?

PDCI Market Access is listed as a direct peer. Broad incumbents are IQVIA, ZS Associates, Trinity Life Sciences, Evidera (PPD / Thermo Fisher) and Syneos Health. Innomar Strategies (Cencora) is listed as a regional player. BresMed is listed as an emerging player.

Does Mapol have an API?

No public API is recorded for Mapol.

What industry is Mapol in?

Mapol's product category is Pharmaceutical Market Access Consulting. Its primary akta.pro industry code is HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales